.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX23_Pralsetinib.Pralsetinib

Information

name:Pralsetinib
ATC code:L01EX23
route:oral
n-compartments2

Pralsetinib is an orally administered, selective RET receptor tyrosine kinase inhibitor used for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant or RET fusion-positive thyroid cancers. It is approved by the FDA and EMA for these indications.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with advanced solid tumors, based on population PK analysis.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos